- May 6, 2021

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- - Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product sales of SIVEXTRO in results of operations-

- Conference call today at 4:30 p.m. Eastern TimeCreate a blog post subtitle that summarizes your post in a few short, punchy sentences and entices your audience to continue reading.

https://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-reports-first-quarter-2021-financial

Recent Posts

See All

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel da

Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual Meeting

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients https://

MatriSys Bioscience Names Joyce Rico as Chief Medical Officer

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD, MBA, FAAD, as Chief Medical Officer. Dr. Rico has over

MESA VERDE

VENTURE PARNERS

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Recent Posts